ATE401339T1 - Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren - Google Patents
Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatorenInfo
- Publication number
- ATE401339T1 ATE401339T1 AT02767028T AT02767028T ATE401339T1 AT E401339 T1 ATE401339 T1 AT E401339T1 AT 02767028 T AT02767028 T AT 02767028T AT 02767028 T AT02767028 T AT 02767028T AT E401339 T1 ATE401339 T1 AT E401339T1
- Authority
- AT
- Austria
- Prior art keywords
- mixtures
- immune modulators
- cyclosporine analogues
- cyclosporine
- analogues
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34620101P | 2001-10-19 | 2001-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401339T1 true ATE401339T1 (de) | 2008-08-15 |
Family
ID=23358378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02767028T ATE401339T1 (de) | 2001-10-19 | 2002-10-17 | Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20110092669A1 (de) |
| EP (2) | EP1816138A1 (de) |
| JP (4) | JP2005511538A (de) |
| KR (1) | KR100992850B1 (de) |
| CN (1) | CN100344648C (de) |
| AR (1) | AR036853A1 (de) |
| AT (1) | ATE401339T1 (de) |
| AU (1) | AU2002331510B2 (de) |
| BE (1) | BE2022C547I2 (de) |
| BR (1) | BR0213659A (de) |
| CA (2) | CA2727642C (de) |
| CO (1) | CO5570682A2 (de) |
| CY (2) | CY1108410T1 (de) |
| DE (1) | DE60227686D1 (de) |
| DK (1) | DK1436322T3 (de) |
| EC (3) | ECSP045059A (de) |
| ES (1) | ES2310604T3 (de) |
| FI (1) | FIC20220041I1 (de) |
| FR (1) | FR22C1051I2 (de) |
| HR (1) | HRP20040353B1 (de) |
| IL (2) | IL160762A0 (de) |
| LT (1) | LTC1436322I2 (de) |
| MA (1) | MA26337A1 (de) |
| ME (1) | ME00487B (de) |
| MX (1) | MXPA04003624A (de) |
| MY (1) | MY187182A (de) |
| NL (1) | NL301200I2 (de) |
| NO (2) | NO331745B1 (de) |
| NZ (1) | NZ531945A (de) |
| PL (1) | PL210697B1 (de) |
| PT (1) | PT1436322E (de) |
| RU (1) | RU2337106C2 (de) |
| SI (1) | SI1436322T1 (de) |
| TN (1) | TNSN04069A1 (de) |
| UY (1) | UY27502A1 (de) |
| WO (1) | WO2003033527A2 (de) |
| ZA (1) | ZA200402270B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100334106C (zh) | 2001-10-19 | 2007-08-29 | 伊索泰克尼卡股份有限公司 | 环孢菌素类似物的合成 |
| ES2310604T3 (es) * | 2001-10-19 | 2009-01-16 | Isotechnika, Inc. | Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores. |
| CA2518265A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| TW200505946A (en) * | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| JP2008514701A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | シクロスポリンアルキン類似体およびそれらの薬学的使用 |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| TW200635954A (en) * | 2004-12-17 | 2006-10-16 | Isotechnika Inc | Metabolites of cyclosporin analogs |
| PT1957518E (pt) * | 2005-10-26 | 2016-02-26 | Astellas Pharma Inc | Novos compostos peptídicos cíclicos |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| JP5459545B2 (ja) * | 2007-05-02 | 2014-04-02 | アステラス製薬株式会社 | 新規環状ペプチド化合物 |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| RU2361604C1 (ru) * | 2007-10-29 | 2009-07-20 | Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) | Способ лечения атопического дерматита |
| WO2010144194A1 (en) | 2009-06-09 | 2010-12-16 | Lux Biosciences, Inc. | Topical drug delivery systems for ophthalmic use |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| CN107496902B (zh) | 2010-12-15 | 2022-01-18 | 康卓维尔制药公司 | 在氨基酸1和3位修改的环孢菌素类似分子 |
| GB201222455D0 (en) | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| EP3549051A4 (de) * | 2016-11-30 | 2020-04-29 | Schrodinger, Inc. | Grafische benutzerschnittstelle für berechnungen von chemischen übergangszuständen |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| WO2018112255A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| US10286036B2 (en) * | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| BR112022018929A2 (pt) * | 2020-03-26 | 2022-12-06 | Farsight Medical Tech Shanghai Co Ltd | Inibidores da ciclofilina e seus usos |
| EP4201952A1 (de) | 2021-12-21 | 2023-06-28 | Curia Spain, S.A.U. | Verfahren zur kontrollierten synthese von voclosporin |
| US20250353880A1 (en) * | 2022-09-09 | 2025-11-20 | Dr. Reddy’S Laboratories Limited | Improved process for the preparation of voclosporin |
| IT202300001116A1 (it) * | 2023-01-25 | 2024-07-25 | Indena Spa | Processo per la preparazione di un intermedio utile per la sintesi di voclosporina |
| IT202300001056A1 (it) * | 2023-01-25 | 2024-07-25 | Procos Spa | Nuovo processo per la preparazione di voclosporina amorfa |
| WO2025119925A1 (en) | 2023-12-05 | 2025-06-12 | Medichem, S.A. | Process for preparing voclosporin |
| WO2025141456A1 (en) * | 2023-12-27 | 2025-07-03 | Indena S.P.A. | Process for the preparation of voclosporin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4278545A (en) * | 1979-09-12 | 1981-07-14 | The Bendix Corporation | Apparatus for separating solids and liquid components |
| CH670644A5 (de) * | 1986-12-18 | 1989-06-30 | Lonza Ag | |
| US5162540A (en) * | 1986-12-18 | 1992-11-10 | Lonza Ltd. | Process for the production of (+) biotin |
| DE3884470T2 (de) * | 1987-06-17 | 1994-03-10 | Sandoz Ag | Cyclosporine und deren Benutzung als Arzneimittel. |
| US5972630A (en) * | 1991-08-19 | 1999-10-26 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using enzyme inhibitors |
| GB9204466D0 (en) * | 1992-03-02 | 1992-04-15 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
| US5750510A (en) * | 1997-04-04 | 1998-05-12 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
| NZ330062A (en) * | 1996-06-19 | 2000-01-28 | Novartis Ag | composition containing cyclosporin, propylene carbonate, an oil component and a surfactant |
| US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
| JP4261049B2 (ja) * | 1997-10-08 | 2009-04-30 | アイソテクニカ インコーポレイテッド | 重水素化シクロスポリンアナログおよび免疫調節剤としてのそれらの使用 |
| ES2310604T3 (es) * | 2001-10-19 | 2009-01-16 | Isotechnika, Inc. | Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores. |
| CN100334106C (zh) * | 2001-10-19 | 2007-08-29 | 伊索泰克尼卡股份有限公司 | 环孢菌素类似物的合成 |
-
2002
- 2002-10-17 ES ES02767028T patent/ES2310604T3/es not_active Expired - Lifetime
- 2002-10-17 SI SI200230742T patent/SI1436322T1/sl unknown
- 2002-10-17 CN CNB02820798XA patent/CN100344648C/zh not_active Expired - Lifetime
- 2002-10-17 EP EP07106871A patent/EP1816138A1/de not_active Withdrawn
- 2002-10-17 RU RU2004110941/04A patent/RU2337106C2/ru active
- 2002-10-17 UY UY27502A patent/UY27502A1/es not_active Application Discontinuation
- 2002-10-17 AT AT02767028T patent/ATE401339T1/de active
- 2002-10-17 CA CA2727642A patent/CA2727642C/en not_active Expired - Lifetime
- 2002-10-17 WO PCT/CA2002/001560 patent/WO2003033527A2/en not_active Ceased
- 2002-10-17 ME MEP-2008-780A patent/ME00487B/me unknown
- 2002-10-17 MX MXPA04003624A patent/MXPA04003624A/es active IP Right Grant
- 2002-10-17 IL IL16076202A patent/IL160762A0/xx unknown
- 2002-10-17 PT PT02767028T patent/PT1436322E/pt unknown
- 2002-10-17 KR KR1020047005721A patent/KR100992850B1/ko not_active Expired - Lifetime
- 2002-10-17 NZ NZ531945A patent/NZ531945A/en not_active IP Right Cessation
- 2002-10-17 AR ARP020103918A patent/AR036853A1/es not_active Application Discontinuation
- 2002-10-17 HR HRP20040353AA patent/HRP20040353B1/hr not_active IP Right Cessation
- 2002-10-17 EP EP02767028A patent/EP1436322B1/de not_active Expired - Lifetime
- 2002-10-17 JP JP2003536265A patent/JP2005511538A/ja not_active Withdrawn
- 2002-10-17 MY MYPI20023885A patent/MY187182A/en unknown
- 2002-10-17 DE DE60227686T patent/DE60227686D1/de not_active Expired - Lifetime
- 2002-10-17 BR BR0213659-7A patent/BR0213659A/pt not_active IP Right Cessation
- 2002-10-17 CA CA2460685A patent/CA2460685C/en not_active Expired - Lifetime
- 2002-10-17 PL PL370501A patent/PL210697B1/pl unknown
- 2002-10-17 AU AU2002331510A patent/AU2002331510B2/en not_active Expired
- 2002-10-17 DK DK02767028T patent/DK1436322T3/da active
-
2004
- 2004-03-05 IL IL160762A patent/IL160762A/en active IP Right Grant
- 2004-03-23 ZA ZA2004/02270A patent/ZA200402270B/en unknown
- 2004-03-26 MA MA27598A patent/MA26337A1/fr unknown
- 2004-04-14 EC EC2004005059A patent/ECSP045059A/es unknown
- 2004-04-14 EC EC2004005060A patent/ECSP045060A/es unknown
- 2004-04-14 EC EC2004005061A patent/ECSP045061A/es unknown
- 2004-04-16 TN TNP2004000069A patent/TNSN04069A1/en unknown
- 2004-04-19 CO CO04035672A patent/CO5570682A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042029A patent/NO331745B1/no not_active IP Right Cessation
-
2008
- 2008-10-13 CY CY20081101130T patent/CY1108410T1/el unknown
-
2009
- 2009-06-11 JP JP2009140608A patent/JP5272140B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-02 JP JP2010151859A patent/JP2011006417A/ja active Pending
- 2010-12-23 US US12/977,602 patent/US20110092669A1/en not_active Abandoned
-
2013
- 2013-01-31 JP JP2013017448A patent/JP2013136597A/ja active Pending
-
2014
- 2014-03-18 US US14/217,827 patent/US20140288266A1/en not_active Abandoned
-
2022
- 2022-10-14 BE BE2022C547C patent/BE2022C547I2/nl unknown
- 2022-10-14 LT LTPA2022521C patent/LTC1436322I2/lt unknown
- 2022-10-14 NO NO2022042C patent/NO2022042I1/no unknown
- 2022-10-14 CY CY2022030C patent/CY2022030I2/el unknown
- 2022-10-14 FR FR22C1051C patent/FR22C1051I2/fr active Active
- 2022-10-14 NL NL301200C patent/NL301200I2/nl unknown
- 2022-10-14 FI FIC20220041C patent/FIC20220041I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401339T1 (de) | Mischungen von cyclosporin-analogen und ihre verwendung als immunmodulatoren | |
| DE60227301D1 (de) | Strukturen von anschlusselementen und anzuschliessende komponente | |
| DE60206344D1 (de) | Baueinheit von Leuchten und Zubehör | |
| DE60219682D1 (de) | Harnstofe von 2-aminobenzothiazolen als adenosin-modulatoren | |
| ATE280163T1 (de) | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren | |
| DE50115561D1 (de) | Spektralphotometer und Verwendung desselben | |
| DE50212455D1 (de) | Verwendung von Dimerdiolen | |
| ATE336169T1 (de) | Verwendung von fettalkoholethoxylaten als penetrationsförderer | |
| ATE309987T1 (de) | Substituierte benzamide und ihre verwendung als immunmodulatoren | |
| BRPI0208558A2 (pt) | preparado de combinação de estrogênio-gestagênio e uso | |
| DE60230883D1 (de) | Neue formulierungen und ihre verwendung | |
| EP1499186A4 (de) | Verwendung von häm-oxygenase-1 und häm-abbauprodukte | |
| PT1390516E (pt) | Novos vectores de expressão e uso dos mesmos | |
| ATE368225T1 (de) | Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe | |
| DE60230438D1 (de) | Racemat von tamsulosin als freie base und dessen herstellungsverfahren | |
| ATE337845T1 (de) | Verwendung von polymerisaten als filterhilfs- und/oder stabilisierungsmittel | |
| DE60313895D1 (de) | 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren | |
| DE60121951D1 (de) | Charakterisierung nichtlinearen Verhaltens | |
| DE60123704D1 (de) | Unterdrückung von Bildern und dazugehöriges Anzeigesystem | |
| DE50210920D1 (de) | Verwendung von Aluminiumchlorohydrat in Deodoranten und Antiperspiranten | |
| DE50103536D1 (de) | Verwendung von kationischen Zubereitungen | |
| DE50202730D1 (de) | Substituierte isoindole und ihre verwendung | |
| DE60237741D1 (de) | Umstellung von Maschinen- und Last-Charakteristik | |
| DE60318819D1 (de) | Hitzestabile mutanten von stärkebiosyntheseenzymen | |
| DE69832902D1 (de) | Oromukosal-zytokin-zusammensetzungen und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1436322 Country of ref document: EP |